Uploaded August 2026 | Updated September 2026, 4 days ago
Host Catherine Murray sits down with Eden Rahim, Portfolio Manager & Options Strategist at Next Edge Capital, to discuss one of the biggest biotech stories of the year: Moderna's breakthrough personalized cancer vaccine developed alongside Merck. Rahim explains why the Phase 3 melanoma trial has generated such excitement across the biotech sector, how mRNA technology could reshape cancer treatment, and whether investors should still consider Moderna after its dramatic rally.
TIMESTAMPS
00:00 Introduction and welcome back to Eden Rahim
00:25 Moderna and Merck's cancer vaccine breakthrough explained
01:36 How the Phase 3 melanoma trial worked
02:29 Why the trial results are so significant
03:17 How personalized mRNA cancer vaccines work
04:31 Have Moderna and Merck cracked the code?
05:21 Why Moderna's stock surged after the announcement
07:10 Can this technology be applied to other cancers?
08:09 Is Moderna still a buy after the rally?
10:47 Why Moderna is a thematic biotech investment
12:18 Biotech's resurgence and investor interest
12:37 Alpha Cognition and Alzheimer's treatment opportunities
15:08 The future of Alzheimer's research
16:19 Why a breakthrough in Alzheimer's could be coming
17:03 The challenges of developing CNS therapies
18:00 ClearPoint Neuro and brain drug delivery technology
20:10 Applications for brain cancer and neurological diseases
21:02 Cytokinetics and opportunities in heart disease treatment
21:27 Final thoughts and wrap-up
GUESTS
• Eden Rahim — Portfolio Manager & Options Strategist, Next Edge Capital
The Buck Stops Here
Host: Catherine Murray
FOLLOW US
• Subscribe: youtube.com/@TheNewsForum
• Twitter/X: https://x.com/thenewsforum_
• LinkedIn: linkedin.com/company/the-news-forum
TAGS
#Biotech #Moderna #MRNA #CancerVaccine #HealthcareInvesting #Biotechnology #Investing #Stocks #StockMarket #Alzheimers #AlphaCognition #ClearPointNeuro #Cytokinetics #Merck #Healthcare #MedicalInnovation #NextEdgeCapital #EdenRahim #CatherineMurray #TheBusinessOfLife
Host Catherine Murray sits down with Eden Rahim, Portfolio Manager & Options Strategist at Next Edge Capital, to discuss one of the biggest biotech stories of the year: Moderna's breakthrough personalized cancer vaccine developed alongside Merck. Rahim explains why the Phase 3 melanoma trial has generated such excitement across the biotech sector, how mRNA technology could reshape cancer treatment, and whether investors should still consider Moderna after its dramatic rally.
TIMESTAMPS
00:00 Introduction and welcome back to Eden Rahim
00:25 Moderna and Merck's cancer vaccine breakthrough explained
01:36 How the Phase 3 melanoma trial worked
02:29 Why the trial results are so significant
03:17 How personalized mRNA cancer vaccines work
04:31 Have Moderna and Merck cracked the code?
05:21 Why Moderna's stock surged after the announcement
07:10 Can this technology be applied to other cancers?
08:09 Is Moderna still a buy after the rally?
10:47 Why Moderna is a thematic biotech investment
12:18 Biotech's resurgence and investor interest
12:37 Alpha Cognition and Alzheimer's treatment opportunities
15:08 The future of Alzheimer's research
16:19 Why a breakthrough in Alzheimer's could be coming
17:03 The challenges of developing CNS therapies
18:00 ClearPoint Neuro and brain drug delivery technology
20:10 Applications for brain cancer and neurological diseases
21:02 Cytokinetics and opportunities in heart disease treatment
21:27 Final thoughts and wrap-up
GUESTS
• Eden Rahim — Portfolio Manager & Options Strategist, Next Edge Capital
The Buck Stops Here
Host: Catherine Murray
FOLLOW US
• Subscribe: youtube.com/@TheNewsForum
• Twitter/X: https://x.com/thenewsforum_
• LinkedIn: linkedin.com/company/the-news-forum
TAGS
#Biotech #Moderna #MRNA #CancerVaccine #HealthcareInvesting #Biotechnology #Investing #Stocks #StockMarket #Alzheimers #AlphaCognition #ClearPointNeuro #Cytokinetics #Merck #Healthcare #MedicalInnovation #NextEdgeCapital #EdenRahim #CatherineMurray #TheBusinessOfLife
